New 'Living Drug' trial targets deadly cancer mutation
Disease control
Ongoing
This early-stage study is testing a new type of personalized cell therapy for people with advanced colorectal, pancreatic, or non-small cell lung cancer. The therapy involves collecting a patient's own immune cells, genetically modifying them to target a specific cancer-causing m…
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Mar 23, 2026 15:28 UTC